MEI Pharma Archives | Be Korea-savvy

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML After Completing Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announce that an interim futility analysis of the ongoing Phase 3 [...]

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the Design of the Phase III PRIMULA Study of Pracinostat in Combination with Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

Lugano, Switzerland, May 30 (Korea Bizwire) – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announce that the PRIMULA study design will be presented at [...]